Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

Rezolute Reports First Quarter Fiscal 2022 Financial

Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., November 12, 2021 (GLOBE NEWSWIRE) -

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative

therapies for metabolic diseases associated with chronic glucose imbalance, today announced its financial results for the first

quarter of fiscal 2022 ended September 30, 2021.

"This has been a productive quarter of execution for Rezolute,

with steady clinical advancement of our lead pipeline candidates, RZ358 and RZ402, in Phase 2b and Phase 1b development, respectively,"

said Nevan Elam, Chief Executive Officer and Founder of Rezolute. "We look forward to announcing topline data for both programs

in Q1 of 2022. Additionally, with a strengthened balance sheet following our recent offering, raising $55 million in gross proceeds, we

have extended our cash runway and are well-positioned to continue to execute on our key clinical milestones."

Recent Business Highlights

First Quarter Fiscal 2022 Financial Results

About Rezolute, Inc.

Rezolute is developing transformative therapies for metabolic diseases related to chronic glucose imbalance. The Company's lead

clinical asset, RZ358, is in Phase 2b development for treatment of congenital hyperinsulinism (HI), a rare pediatric endocrine disorder.

The Company is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For

Forward-Looking Statements

This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain

forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act

and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe

harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and are including this

statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe

future plans, strategies, and expectations of the Company, are generally identified by use of words such as "anticipate," "believe,"

"estimate," "expect," "intend," "plan," "project," "seek," "strive,"

"try," or future or conditional verbs such as "could," "may," "should," "will," "would,"

or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly,

actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking

statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no

obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements

Media and Investor Contact

Condensed Consolidated Financial Statements Data

(in thousands, except per share data)